Haemonetics Corporation (HAE)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Haemonetics Corporation (HAE)
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Key Insights
Critical company metrics and information
Share Price
$83.55Market Cap
$4.20 BillionTotal Outstanding Shares
50.22 Million SharesTotal Employees
3,657Dividend
No dividendIPO Date
May 9, 1991SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.haemonetics.com
Historical Stock Splits
If you bought 1 share of HAE before December 3, 2012, you'd have 2 shares today.
Execution Date | Split Amount |
---|---|
December 3, 2012 | 2-for-1 |
Cash Flow Statement
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $-54.80 Million |
Net Cash Flow From Operating Activities | $84.94 Million |
Exchange Gains/Losses | $3.08 Million |
Net Cash Flow From Financing Activities | $304.81 Million |
Net Cash Flow From Investing Activities | $-444.56 Million |
Net Cash Flow From Investing Activities, Continuing | $-444.56 Million |
Net Cash Flow | $-51.72 Million |
Net Cash Flow From Financing Activities, Continuing | $304.81 Million |
Net Cash Flow From Operating Activities, Continuing | $84.94 Million |
Income Statement
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Diluted Earnings Per Share | $2.41 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Average Shares | $102.85 Million |
Depreciation and Amortization | $109.52 Million |
Operating Income/Loss | $167.37 Million |
Net Income/Loss Available To Common Stockholders, Basic | $123.81 Million |
Revenues | $1.36 Billion |
Net Income/Loss Attributable To Parent | $123.81 Million |
Income/Loss From Continuing Operations Before Tax | $158.86 Million |
Basic Earnings Per Share | $2.44 |
Cost Of Revenue | $645.09 Million |
Basic Average Shares | $101.72 Million |
Income/Loss From Continuing Operations After Tax | $123.81 Million |
Gross Profit | $716.13 Million |
Research and Development | $60.10 Million |
Net Income/Loss | $123.81 Million |
Selling, General, and Administrative Expenses | $448.59 Million |
Operating Expenses | $548.76 Million |
Benefits Costs and Expenses | $1.20 Billion |
Income Tax Expense/Benefit, Deferred | $-15.16 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income Tax Expense/Benefit | $35.05 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Costs And Expenses | $1.20 Billion |
Balance Sheet
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Intangible Assets | $487.84 Million |
Inventory | $382.11 Million |
Wages | $49.30 Million |
Liabilities And Equity | $2.53 Billion |
Assets | $2.53 Billion |
Current Assets | $955.90 Million |
Noncurrent Liabilities | $1.37 Billion |
Liabilities | $1.65 Billion |
Noncurrent Assets | $1.57 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Liabilities | $273.95 Million |
Other Non-current Assets | $781.01 Million |
Fixed Assets | $300.48 Million |
Equity | $878.85 Million |
Equity Attributable To Parent | $878.85 Million |
Other Current Liabilities | $155.40 Million |
Accounts Payable | $69.24 Million |
Other Current Assets | $573.80 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Haemonetics Corporation (HAE)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.